Fat Burner Letrozole Product for Sale

Fat Burner Letrozole Product for Sale

Letrozole is rapidly and completely absorbed from the gastrointestinal tract (GIT), the average bioavailability is 99.9%. Food intake slightly reduces the absorption rate. Average value of time of maximum letrozole concentration in blood (ТСmax) is 1 hour when letrozole is taken on an empty stomach and 2 hours – when it is taken with food; average value of maximum concentration (Сmax) is 129 ± 20.3 nmol/l in fasting state and 98.7 ± 18.6 nmol/l – in food, but degree of letrozole absorption (when estimated by area under curve “concentration-time” (AUC)) is not changed. Slight changes in absorption rate are regarded as having no clinical significance, so letrozole can be taken regardless of food intake.

Description of the fat burner Letrozole

The binding of letrozole with blood plasma proteins is approximately 60% (predominantly with albumin – 55%). Letrozole concentration in erythrocytes is about 80% of that in blood plasma. The apparent volume of distribution in equilibrium is about 1.87 ± 0.47 l/kg. The equilibrium concentration is reached within 2-6 weeks of daily administration of a daily dose of 2.5 mg. Pharmacokinetics is non-linear. No cumulation during long-term use has been noted.

Letrozole is largely metabolized by CYP3A4 and CYP2A6 cytochrome P450 isoenzymes to form pharmacologically inactive carbinol compound. It is excreted mainly by the kidneys as metabolites, and to a lesser extent – through the intestines. Final elimination half-life (T1/2) is 48 hours.

Pharmacokinetic parameters of letrozole do not depend on the age of the patient. In renal failure pharmacokinetic parameters do not change. In moderately expressed hepatic impairment (class B according to Child-Pugh scale) mean AUC values, although higher by 37%, but remain within the range of values that are observed in patients without liver impairment. In patients with cirrhosis and severe liver dysfunction (class C according to Child-Pugh scale) AUC is increased by 95% and T1/2 – by 187%. However, taking into account good tolerability of high doses of the drug (5-10 mg/day) in these cases there is no need to change the dose of letrozole.

See also  Letrozole Drug Review

Sale of Letrozole in bodybuilding

Letrozole is a drug used to treat breast cancer in women. It is in a class of medications called aromatase inhibitors. It works by stopping the body from making estrogen. Estrogen can promote the growth of some types of breast cancer cells. The U.S. Food and Drug Administration (FDA) has approved letrozole for the treatment of postmenopausal women with estrogen receptor-positive (ER+) advanced breast cancer who have received prior anti-estrogen therapy.

Sale of Letrozole in bodybuilding

Letrozole has an anti-estrogenic effect, it selectively inhibits aromatase (an enzyme of estrogen synthesis) by a highly specific competitive binding to a subunit of this enzyme – cytochrome P450 heme. It blocks the synthesis of estrogens in both peripheral and tumor tissues. In postmenopausal women, estrogens are formed mainly with the participation of aromatase enzyme, which converts androgens synthesized in adrenal glands (primarily androstenedione and testosterone) into estrone and estradiol.

Daily administration of letrozole at a daily dose of 0.1-5 mg leads to a decrease in plasma concentrations of estradiol, estrone and estrone sulfate by 75-95% of the initial content. Suppression of estrogen synthesis is maintained throughout the treatment period. When using letrozole in the dose range from 0.1 to 5 mg, no disruption of steroid hormone synthesis in the adrenal glands is observed, the test with adrenocorticotropic hormone (ACTH) reveals no disruption of aldosterone or cortisol synthesis. No additional administration of glucocorticoids or mineralocorticoids is required. Blockade of estrogen biosynthesis does not lead to accumulation of androgens, which are precursors of estrogens. No changes in plasma concentrations of luteinizing and follicle stimulating hormones, changes in thyroid function, changes in lipid profile, increased incidence of myocardial infarctions and strokes have been noted during letrozole treatment.

See also  Letrozole Is an Effective Inhibitor for Men

Against the background of letrozole treatment the incidence of osteoporosis slightly increased (6.9% compared to 5.5% on placebo). However, the incidence of bone fractures in patients receiving letrozole does not differ from that in healthy people of the same age. Adjuvant letrozole therapy for early-stage breast cancer reduces the risk of recurrence, increases survival without signs of disease for 5 years, and reduces the risk of developing secondary tumors.

Everyone can buy the drug online

Everyone can buy the drug online

There are a number of different fat burners on the market, but one of the most popular is Letrozole. This product is available for sale online, and it can help you lose weight quickly and safely. Letrozole is a powerful product that can help you burn fat quickly, and it also has other benefits, such as increasing your energy levels and helping to improve your mood. If you’re looking for a safe and effective way to lose weight, then consider buying Letrozole.

If you are looking to buy a quality fat burner, then Letrozole may be the perfect choice for you. This product is available for sale online, and it can help you lose weight quickly and safely. Letrozole is a powerful drug that can help you burn fat quickly, and it is also known for its anti-estrogen effects. When used correctly, Letrozole can help you achieve your weight loss goals in a short amount of time.

Are you looking for a product to help you burn fat? Letrozole is a drug that can help you do just that. It is used to treat breast cancer, but it has also been shown to be effective in burning fat. It works by blocking the effects of estrogen in the body. This causes the body to break down more fat. You can buy Letrozole online, and the price will vary depending on the supplier.

See also  Side Effects of the Fat Burner Letrazole

Letrozole is a non-steroidal aromatase inhibitor (inhibitor of estrogen biosynthesis), an antitumor drug. In cases where tumor tissue growth depends on the presence of estrogen, elimination of estrogen-mediated stimulating effects is a prerequisite for suppressing tumor growth. In postmenopausal women, estrogens are formed primarily by the aromatase enzyme, which converts androgens that are synthesized in the adrenal glands (primarily androstenedione and testosterone) into estrone (E1) and estradiol (E2). Therefore, by specific inhibition of the aromatase enzyme, suppression of estrogen biosynthesis in peripheral tissues and in tumor tissue can be achieved. Letrozole inhibits aromatase by competitive binding to a subunit of this enzyme, the cytochrome P450 heme, which leads to a decrease in estrogen biosynthesis in all tissues.

In healthy postmenopausal women, a single dose of letrozole, which is 0.1 mg, 0.5 mg and 2.5 mg, reduces serum estrone and estradiol levels (compared to baseline) by 75-78% and 78%, respectively . The maximum reduction is achieved after 48-78 hours.